<a href="https://laohu8.com/S/TELO">Telomir Pharmaceuticals</a> to Acquire TELI Pharmaceuticals in Stock-for-Stock Deal
Telomir Pharmaceuticals, Inc. has entered into a binding Letter of Intent with TELI Pharmaceuticals, Inc. to acquire all outstanding shares of TELI through a stock-for-stock exchange. The agreement will consolidate worldwide intellectual property and development rights for Telomir-1, an oral epigenetic therapy in preclinical development for cancer, aging, and age-related diseases. The exchange ratio for the shares will be determined by an independent third-party valuation. Certain TELI shareholders have committed up to $5 million in cash contributions to support the transaction and future development, with milestone-based payments tied to regulatory and clinical progress for Telomir-1. The agreement includes a six-month lockup period for the shares to be issued and unifies global rights to streamline development and partnership activities. Completion remains subject to due diligence, approvals, and execution of definitive agreements.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-018634), on October 20, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.